TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12360108

Group type: EXPERIMENTAL
Intervention: Pranlukast (225 mg twice daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Inhaled beta-agonist salbutamol (200 microg)
Number of subjects: 50
Study: 10548658

Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator (rtPA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: No hemorrhagic transformation
Number of subjects: 0
Study: 8894912

Group type: EXPERIMENTAL
Intervention: Denser reinforcement schedules
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Behavioral momentum predictions
Number of subjects: 8
Study: 1997062

Group type: COMPARATOR
Intervention: Ringer lactate
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Human albumin (4%)
Number of subjects: 20
Study: 6148572

Group type: EXPERIMENTAL
Intervention: Vaccine aerosol given by mask at a dose of 3500 or 7000 PFU
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Vaccine aerosol given from a plastic bag at a dose of 7000 PFU
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: 11 400 PFU of vaccine intradermally in two divided doses
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: 39 000 PFU of the virus subcutaneously
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: All vaccinated children
Number of subjects: 93
Study: 31786963

Group type: EXPERIMENTAL
Intervention: Short-term integrated rehabilitation
Number of subjects: 54

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 54
Study: 30196837

Group type: EXPERIMENTAL
Intervention: Interferon-beta (IFNB) treatment
Number of subjects: 88

Group type: COMPARATOR
Intervention: No immunomodulatory treatment
Number of subjects: 88
Study: 27184495

Group type: EXPERIMENTAL
Intervention: teneligliptin
Number of subjects: 45

Group type: COMPARATOR
Intervention: sitagliptin
Number of subjects: 45
Study: 24362488

Group type: EXPERIMENTAL
Intervention: Ponesimod (40 mg) with combined oral contraceptive (1 mg norethisterone and 35 μg ethinyl estradiol)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Ponesimod (10 mg)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Ponesimod (20 mg)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Ponesimod (40 mg)
Number of subjects: 22
Study: 22985676

Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR-NTX)
Number of subjects: 65
Study: 20197194

Group type: EXPERIMENTAL
Intervention: Swimming
Number of subjects: 116

Group type: COMPARATOR
Intervention: Walking
Number of subjects: 116
Study: 17653486

Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum (109 CFU/day)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Bifidobacterium lactis Bb12 (109 CFU/day)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Placebo (without viable bacteria)
Number of subjects: 209
Study: 16283905

Group type: EXPERIMENTAL
Intervention: Facial moisturizer with diazolidinyl urea concentrations ranging from 0.05% to 0.6%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group with the test product containing increasing preservative concentrations
Number of subjects: 0
Study: 11857045

Group type: EXPERIMENTAL
Intervention: MCT/LCT (50/50) supplemented with 100 mg DL-alpha-tocopherol/day
Number of subjects: 24

Group type: COMPARATOR
Intervention: LCT
Number of subjects: 24
Study: 10404024

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT) (cyclic estradiol/norethisterone acetate)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT)
Number of subjects: 35
Study: 7564082

Group type: EXPERIMENTAL
Intervention: OPC‐31260 (1 mg/kg body wt)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OPC‐31260 (low dose unspecified)
Number of subjects: 0
Study: 2188795

Group type: EXPERIMENTAL
Intervention: 150 mg trazodone at night
Number of subjects: 228

Group type: COMPARATOR
Intervention: 75 mg dothiepin at night
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 228

Group type: COMPARATOR
Intervention: Dothiepin
Number of subjects: 228
Study: 6996149

Group type: EXPERIMENTAL
Intervention: Isopyrine 240 mg plus phenylbutazone 130 mg (Tomanol)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 30883495

Group type: EXPERIMENTAL
Intervention: Constant practice (2:1 speed ratio)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Variable practice (3 different speed ratios)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Both groups (constant and variable practice)
Number of subjects: 32
Study: 28633773

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) - 15 sessions (8 J/cm2; 830 nm)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT) - 3 sessions (2000 shocks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Therapeutic ultrasound (US) therapy - 15 sessions (1 mHz; 2 W/cm2)
Number of subjects: 60
Study: 25934413

Group type: EXPERIMENTAL
Intervention: Community awareness programme (psycho-educational workshops and EIS link workers)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Community awareness programme
Number of subjects: 110
Study: 24098630

Group type: EXPERIMENTAL
Intervention: Training towards negative cues
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Training towards positive cues
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control training condition
Number of subjects: 129
Study: 21813443

Group type: EXPERIMENTAL
Intervention: 3 mL of PRP
Number of subjects: 28

Group type: COMPARATOR
Intervention: 3 mL of autologous blood
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both groups (PRP and autologous blood)
Number of subjects: 28
Study: 19764189

Group type: EXPERIMENTAL
Intervention: Training programme designed to reduce the risk of occupational injuries
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 17538085

Group type: EXPERIMENTAL
Intervention: Surgical treatment (decompressive laminectomy with or without fusion)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Nonsurgical treatment (usual nonsurgical care)
Number of subjects: 304
Study: 15155346

Group type: EXPERIMENTAL
Intervention: 1% ropivacaine
Number of subjects: 54

Group type: COMPARATOR
Intervention: 0.1% ropivacaine
Number of subjects: 54
Study: 11431663

Group type: EXPERIMENTAL
Intervention: Dofetilide 500 microg twice daily
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Propafenone 150 mg three times a day
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study: 9529685

Group type: EXPERIMENTAL
Intervention: Oral terbinafine 250 mg daily for 12 weeks
Number of subjects: 111
Study: 9236419

Group type: EXPERIMENTAL
Intervention: Patients with peripheral arterial disease (n=64)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control subjects (n=64)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Patients with major vascular events (n=8)
Number of subjects: 128
Study: 2018012

Group type: EXPERIMENTAL
Intervention: Metoprolol CR, 200 mg once daily
Number of subjects: 65

Group type: COMPARATOR
Intervention: Nifedipine retard 20 mg twice daily
Number of subjects: 65
Study: 7037501

Group type: EXPERIMENTAL
Intervention: Psoradrate 0.1%
Number of subjects: 49

Group type: COMPARATOR
Intervention: Dithrocream 0.1%
Number of subjects: 49
Study: 31089856

Group type: EXPERIMENTAL
Intervention: Productive failure (attempt to generate solutions before receiving instruction)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Direct instruction only
Number of subjects: 40
Study: 28987039

Group type: EXPERIMENTAL
Intervention: Bioceramic undershirt (EG)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo group (PG)
Number of subjects: 39
Study: 25122521

Group type: EXPERIMENTAL
Intervention: REMau cognitive training programme for autobiographical memory
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive training programme focused on collective semantic memory
Number of subjects: 0
Study: 23849046

Group type: EXPERIMENTAL
Intervention: Consultations with a Cardiometabolic Health Nurse
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 22091554

Group type: EXPERIMENTAL
Intervention: Countermeasure groups with 50% and 75% irrelevant stimuli
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simple guilty (no countermeasure use)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Innocent subjects
Number of subjects: 0
Study: 19284108

Group type: EXPERIMENTAL
Intervention: Phytoaeroionotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of magnetopuncture and phytoaeroionotherapeutic chronocorrection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of soft‐tissue manual therapy
Number of subjects: 0
Study: 17547587

Group type: EXPERIMENTAL
Intervention: Quetiapine 600 mg/day
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Quetiapine 300 mg/day
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Quetiapine (600 and 300 mg/day)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 108
Study: 14999693

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics (ofloxacin 200 mg i.v. q12h for 2 days followed by oral ofloxacin 200 mg q12h for 5 days)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics
Number of subjects: 120

Group type: COMPARATOR
Intervention: On-demand antibiotics
Number of subjects: 120
Study: 12108078

Group type: EXPERIMENTAL
Intervention: Lactose containing formula (Bebilon Neonatal - BN group)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Lactose free formula (Pregestimil - PG group)
Number of subjects: 80
Study: 9337185

Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 1829

Group type: COMPARATOR
Intervention: CABG
Number of subjects: 1829

Group type: EXPERIMENTAL
Intervention: Combined endpoint (cardiac death or MI)
Number of subjects: 1829

Group type: EXPERIMENTAL
Intervention: MI after CABG
Number of subjects: 1829

Group type: EXPERIMENTAL
Intervention: MI after PTCA
Number of subjects: 1829

Group type: EXPERIMENTAL
Intervention: MI
Number of subjects: 1829
Study: 8461240

Group type: EXPERIMENTAL
Intervention: Sustained-release ibuprofen (once-daily dosing)
Number of subjects: 578

Group type: COMPARATOR
Intervention: Conventional-release ibuprofen (400 mg four times daily)
Number of subjects: 578
Study: 2879733

Group type: COMPARATOR
Intervention: Atenolol 100 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Bisoprolol 20 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 28335697

Group type: EXPERIMENTAL
Intervention: Individually tailored cognitive-behavioral therapy program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 25673525

Group type: EXPERIMENTAL
Intervention: Family partnership intervention
Number of subjects: 117

Group type: COMPARATOR
Intervention: Patient-family education
Number of subjects: 117

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 117
Study: 25332473

Group type: EXPERIMENTAL
Intervention: High protein intake (30%E) with low saturated fat (7%E)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Moderate protein intake (20%E) with low saturated fat (7%E)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: High protein intake (30%E) with high saturated fat (15%E)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Moderate protein intake (20%E) with high saturated fat (15%E)
Number of subjects: 158
Study: 22962239

Group type: COMPARATOR
Intervention: Deworming tablet (400 mg albendazole) once in six months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deworming tablet (400 mg albendazole) plus weekly Iron-Folic acid (60 mg elemental iron and 0.5 mg folic acid)
Number of subjects: 0
Study: 20456032

Group type: EXPERIMENTAL
Intervention: Opaque layer firing temperature at 950 degrees C (Gr2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Opaque layer firing temperature at 1000 degrees C (Gr3)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Opaque layer firing temperature at 900 degrees C (Gr1, control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mechanical and thermal cycling
Number of subjects: 60
Study: 19093922

Group type: EXPERIMENTAL
Intervention: Clinical decision support system in intervention units
Number of subjects: 1118

Group type: COMPARATOR
Intervention: No clinical decision support system in control units
Number of subjects: 1118
Study: 15795344

Group type: EXPERIMENTAL
Intervention: Educational and motivational intervention including an ACP workbook, motivational counseling by social workers, and cues to providers to discuss ACP.
Number of subjects: 248

Group type: COMPARATOR
Intervention: Control group received an advance directive booklet.
Number of subjects: 248
Study: 12487504

Group type: EXPERIMENTAL
Intervention: Trimetazidine
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control
Number of subjects: 44
Study: 10327093

Group type: EXPERIMENTAL
Intervention: Ultrasound therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8959787

Group type: EXPERIMENTAL
Intervention: 3-day course of antithymocyte globulin (ATG)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 10-day course of antithymocyte globulin (ATG)
Number of subjects: 30
Study: 1812477

Group type: EXPERIMENTAL
Intervention: Theophylline retard preparation administered once daily in addition to baseline medication
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Theophylline intake at 10 p.m.
Number of subjects: 26

Group type: COMPARATOR
Intervention: Theophylline intake at 6 p.m. and 8 p.m.
Number of subjects: 26
Study: 6440704

Group type: EXPERIMENTAL
Intervention: Mannitol
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Pentobarbital
Number of subjects: 59
Study: 30417636

Group type: EXPERIMENTAL
Intervention: SQ HDM SLIT-tablet (ACARIZAX®) as add-on to pharmacotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pharmacotherapy alone
Number of subjects: 0
Study: 29324244

Group type: COMPARATOR
Intervention: Advantaged social status
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Disadvantaged social status
Number of subjects: 103
Study: 27339453

Group type: EXPERIMENTAL
Intervention: Resveratrol (500 mg capsules, twice daily for 4 weeks)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (500 mg neutral microcellulose capsules, twice daily for 4 weeks)
Number of subjects: 100
Study: 25216506

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention leading to normal glucose tolerance at 6 months (NGT-6 m)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention leading to normal glucose tolerance at 24 months (NGT-24 m)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conversion to T2DM
Number of subjects: 0
Study: 23066166

Group type: EXPERIMENTAL
Intervention: Combined B-vitamin treatment (folic acid 2.5mg, vitamin B(6) 50mg, vitamin B(12) 1mg)
Number of subjects: 5442

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5442

Group type: EXPERIMENTAL
Intervention: Combined B-vitamin treatment
Number of subjects: 5442
Study: 20976051

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP)
Number of subjects: 780

Group type: EXPERIMENTAL
Intervention: Amodiaquine + Sulfadoxine-Pyrimethamine (AQ+SP)
Number of subjects: 780

Group type: EXPERIMENTAL
Intervention: Sulfadoxine-Pyrimethamine (SP)
Number of subjects: 780

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 780
Study: 17610459

Group type: COMPARATOR
Intervention: Progressive muscle relaxation plus guided imagery
Number of subjects: 20

Group type: COMPARATOR
Intervention: Meditation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Tai chi
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Biofeedback
Number of subjects: 20

Group type: COMPARATOR
Intervention: Yoga
Number of subjects: 20

Group type: COMPARATOR
Intervention: Hypnosis
Number of subjects: 20

Group type: COMPARATOR
Intervention: Progressive muscle relaxation
Number of subjects: 20
Study: 16276166

Group type: EXPERIMENTAL
Intervention: Low-dose hydrocortisone (50-mg bolus followed by a continuous infusion of 0.18 mg/kg body weight/hr, reduced to 0.06 mg/kg/hr after shock reversal)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Low-dose hydrocortisone
Number of subjects: 41
Study: 11924224

Group type: EXPERIMENTAL
Intervention: Chewing sugar-free gum (sorbitol-sweetened), 1 stick for 15-20 minutes after meals, three times daily
Number of subjects: 547

Group type: COMPARATOR
Intervention: Control group (no chewing gum)
Number of subjects: 547
Study: 9701189

Group type: EXPERIMENTAL
Intervention: Tomato-based juice supplemented with vitamin C (600 mg), vitamin E (400 IU), and beta-carotene (30 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo juice
Number of subjects: 0
Study: 7648372

Group type: EXPERIMENTAL
Intervention: Budesonide (delivered via Turbuhaler)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (delivered via Rotahaler)
Number of subjects: 16
Study: 2528221

Group type: EXPERIMENTAL
Intervention: Metronidazole 1% cream applied twice daily
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 97
Study: 1182676

Group type: EXPERIMENTAL
Intervention: Methotrexate therapy
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Methotrexate in combination with other drugs
Number of subjects: 195
Study: 31003139

Group type: EXPERIMENTAL
Intervention: Cortisol suppression (metyrapone)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 28815547

Group type: EXPERIMENTAL
Intervention: Adjustable single‐incision mini‐sling (SIMS) (Ajust®; n = 155)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Standard mid‐urethral slings (SMUS) (TVT, TVT‐O or TOT; n = 150)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Adjustable single‐incision mini‐sling (SIMS) (Ajust®)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Standard mid‐urethral slings (SMUS)
Number of subjects: 305
Study: 26119672

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with negative emmprin expression
Number of subjects: 250

Group type: COMPARATOR
Intervention: Cystectomy only cohort with emmprin expression
Number of subjects: 250
Study: 23131078

Group type: EXPERIMENTAL
Intervention: Ultrafiltration
Number of subjects: 188

Group type: COMPARATOR
Intervention: Pharmacologic therapy
Number of subjects: 188
Study: 19409544

Group type: EXPERIMENTAL
Intervention: Culturing embryos at low oxygen (5% O2, 89% N2)
Number of subjects: 647

Group type: COMPARATOR
Intervention: Culturing embryos in air (5% O2)
Number of subjects: 647
Study: 18763475

Group type: EXPERIMENTAL
Intervention: Culturally specific dance
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 126
Study: 15644672

Group type: EXPERIMENTAL
Intervention: Early Enteral Nutrition (EN)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Early Parenteral Nutrition (PN)
Number of subjects: 30
Study: 11911721

Group type: COMPARATOR
Intervention: Low-intensity exercise (LEX, n = 24)
Number of subjects: 62

Group type: COMPARATOR
Intervention: High-intensity exercise (HEX, n = 22)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control (n = 16)
Number of subjects: 62
Study: 10622346

Group type: EXPERIMENTAL
Intervention: Scopolamine (1.5 microg/kg, IM, at 23.00 h)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Scopolamine
Number of subjects: 95
Study: 8748367

Group type: EXPERIMENTAL
Intervention: i.v. nutrition plus triple therapy (heparin, hydrocortisone, glyceryl trinitrate patch)
Number of subjects: 46

Group type: COMPARATOR
Intervention: standard i.v. nutrition (control group)
Number of subjects: 46
Study: 2117424

Group type: EXPERIMENTAL
Intervention: Vamin 9 glucose
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: MB233G
Number of subjects: 68
Study: 6795122

Group type: EXPERIMENTAL
Intervention: O-acetyl-negative polysaccharide vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: O-acetyl-positive polysaccharide vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 0
Study: 29890569

Group type: COMPARATOR
Intervention: Sitagliptin 50 mg daily plus placebo
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Sitagliptin 50 mg daily plus synbiotic
Number of subjects: 138
Study: 26303349

Group type: EXPERIMENTAL
Intervention: Moderate to vigorous physical activity (MVPA)
Number of subjects: 510

Group type: COMPARATOR
Intervention: Sedentary time (SED)
Number of subjects: 510
Study: 25023805

Group type: EXPERIMENTAL
Intervention: MFG and BA (combined)
Number of subjects: 448

Group type: COMPARATOR
Intervention: Control (no MFG or BA)
Number of subjects: 448
Study: 22682022

Group type: EXPERIMENTAL
Intervention: More Intensive (MI) regimen of tofacitinib
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Less Intensive (LI) regimen of tofacitinib
Number of subjects: 331

Group type: COMPARATOR
Intervention: Cyclosporine (CsA)
Number of subjects: 331
Study: 20860917

Group type: EXPERIMENTAL
Intervention: Montek®
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Tomont®
Number of subjects: 24

Group type: COMPARATOR
Intervention: Singulair®
Number of subjects: 24
Study: 19072676

Group type: EXPERIMENTAL
Intervention: DBT skills utilization
Number of subjects: 27
Study: 15894592

Group type: EXPERIMENTAL
Intervention: Protein‐energy supplementation (Atole)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Low energy/no protein supplementation (Fresco)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Atole group
Number of subjects: 450
Study: 12567341

Group type: EXPERIMENTAL
Intervention: Interscalene block
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Supraclavicular block
Number of subjects: 18

Group type: COMPARATOR
Intervention: Infraclavicular block
Number of subjects: 18
Study: 10575074

Group type: EXPERIMENTAL
Intervention: Gait with shoes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gait without shoes
Number of subjects: 0
Study: 8757085

Group type: EXPERIMENTAL
Intervention: Purified propolis
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Propolis saturated with anti-inflammatory trace metal elements
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Propolis saturated with trace metal elements
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Poplar bud ointment saturated with trace metal elements
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 190